rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2409-2231-2019-6-4-6rpmj-461Research ArticleОригинальные статьи. Онкология, лучевая терапияOriginal Articles. ОncologyАктивация разных систем факторов роста в ткани аденокарциномы и перстневидноклеточного рака желудкаActivation of different growth factor systems in tissues of adenocarcinoma and signet-ring cell carcinoma of the stomachhttps://orcid.org/0000-0003-3061-6108КитО. И.KitO. I.

Кит Олег Иванович - член-корреспондент РАН, доктор медицинских наук, профессор, генеральный директор.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Oleg I. Kit - member Russian Academy of Sciences, MD, PhD, DSc, professor, general director Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0003-3618-6890ФранциянцЕ. М.FrantsiyantsE. M.

Франциянц Елена Михайловна - доктор биологических наук, профессор, заместитель генерального директора по науке.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Elena M. Frantsiyants - PhD, DSc (Biology), professor, deputy director general for science Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0001-6265-8500ГорошинскаяИ. А.GoroshinskayaI. A.

Горошинская Ирина Александровна - доктор биологических наук, профессор, главный научный сотрудник лаборатории изучения патогенеза злокачественных опухолей.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Irina A. Goroshinskaya - PhD, DSc (Biology), professor, chief researcher of the laboratory for the study of the pathogenesis of malignant tumors Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0002-4318-7587СуриковаЕ. И.SurikovaE. I.

Сурикова Екатерина Игоревна - кандидат биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Ekaterina I. Surikova - PhD (Biology), senior researcher of the laboratory for the study of the pathogenesis of malignant tumors Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

sunsur2000@mail.ruhttps://orcid.org/0000-0002-2302-8271БандовкинаВ. А.BandovkinaV. A.

Бандовкина Валерия Ахтямовна - кандидат биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Valeriya A. Bandovkina - PhD (Biology), senior researcher of the laboratory for the study of the pathogenesis of malignant tumors Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0002-2674-9832ПогореловаЮ. А.PogorelovaYu. A.

Погорелова Юлия Александровна - кандидат биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Yuliya A. Pogorelova - PhD (Biology), senior researcher of the laboratory for the study of the pathogenesis of malignant tumors Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0003-2713-8598НемашкаловаЛ. А.NemashkalovaL. A.

Немашкалова Людмила Анатольевна - научный сотрудник лаборатории изучения патогенеза злокачественных опухолей.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Lyudmila A. Nemashkalova - researcher of the laboratory for the study of the pathogenesis of malignant tumors Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0002-4850-3753МедведеваД. Е.MedvedevaD. E.

Медведева Дарья Евгеньевна - аспирант отделения абдоминальной онкологии № 3.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Darya E. Medvedeva - postgraduate student of abdominal oncology department No. 3 Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0001-7742-4918ШалашнаяЕ. В.ShalashnajaE. V.

Шалашная Елена Владимировна - кандидат биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Elena V. Shalashnaya - PhD (Biology), senior researcher laboratory for the study of the pathogenesis of malignant tumors Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0003-4902-5789МасловА. А.MaslovA. A.

Маслов Андрей Александрович - доктор медицинских наук, профессор, руководитель отделения абдоминальной онкологии № 3.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Andrey A. Maslov - MD, PhD, DSc, professor, head of the department of abdominal oncology No. 3 Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

https://orcid.org/0000-0001-8511-7280СидоренкоЮ. С.SidorenkoYu. S.

Сидоренко Юрий Сергеевич - академик РАН - доктор медицинских наук, профессор, руководитель отдела опухолей репродуктивной системы.

344037, Ростов-на-Дону, ул. 14-я линия, д. 63.

Yuriy S. Sidorenko - academician Russian Academy of Sciences, MD, PhD, DSc, professor, head of the department of reproductive system tumors Rostov Research Institute of Oncology (RRIO).

63 14 line, Rostov-on-Don 344037.

Ростовский научно-исследовательский онкологический институт Министерства здравоохранения Российской ФедерацииРоссияRostov Research Institute of Oncology (RRIO)Russian Federation201928122019646066Copyright © Кит О.И., Франциянц Е.М., Горошинская И.А., Сурикова Е.И., Бандовкина В.А., Погорелова Ю.А., Немашкалова Л.А., Медведева Д.Е., Шалашная Е.В., Маслов А.А., Сидоренко Ю.С., 20192019Кит О.И., Франциянц Е.М., Горошинская И.А., Сурикова Е.И., Бандовкина В.А., Погорелова Ю.А., Немашкалова Л.А., Медведева Д.Е., Шалашная Е.В., Маслов А.А., Сидоренко Ю.С.Kit O.I., Frantsiyants E.M., Goroshinskaya I.A., Surikova E.I., Bandovkina V.A., Pogorelova Y.A., Nemashkalova L.A., Medvedeva D.E., Shalashnaja E.V., Maslov A.A., Sidorenko Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/461Цель исследования

Цель исследования. Установить различия в локальном содержании VEGF, EGF, IGFI и IGFII при аденокарциноме (АК) и перстневидноклеточном раке (ПКР) в опухолевой и визуально неизмененной (интактной) ткани желудка.

Материалы и методы

Материалы и методы. В опухолевой и визуально неизмененной тканях желудка, полученных при хирургическом лечении 15 больных с АК желудка и 10 больных ПКР (T2-3 N0-2 M0, G2-G3, средний возраст 62,8±2,38), стандартными методами иммуноферментного анализа (ИФА) определяли концентрации VEGF, EGF, sEGFR, IGF-I, IGFII.

Результаты

Результаты. Интактная ткань желудка при АК и ПКР не имела отличий по уровню IGF-I, IGF-II и VEGF, но уровни EGF и sEGFR при АК были выше, чем при ПКР. В опухоли АК, по сравнению с интактной тканью, уровень VEGF повышался в 2,3 раза, а уровни IGF снижались: в 2,1 раза IGFI и в 1,8 раза IGFII. В опухоли ПКР повышался только уровень EGF в 2,9 раза и sEGFR в 1,8 раза по сравнению с интактной тканью желудка. Особенностью ПКР оказалась активация систем EGF и IGF, но не VEGF. При АК выявлена стимуляция неоангиогенеза VEGF-А.

Заключение

Заключение. Выявлена значительная разница в уровнях VEGF-А, IGF-I и IGF-II и компонентов системы EGF в опухолевых и визуально интактных тканях при АК G2-G3 и ПКР желудка. Возможно, большая активность систем EGF и IGF при ПКР связана с особенностями диффузного роста и происхождением из нейроэндокринных клеток, что свидетельствует об аутокринной/паракринной регуляции инвазивного роста. АК солидного строения в большей степени нуждается в неоангиогенезе, который осуществляется преимущественно системой VEGF.

Purpose of the study

Purpose of the study. The purpose of the study was to find the difference between local levels of VEGF, EGF, IGFI and IG- FII in tumor and intact tissues in adenocarcinoma of the stomach (AC) and signet-ring cell carcinoma of the stomach (SRCC).

Materials and methods

Materials and methods. Levels of VEGF, EGF, EGFR, IGF-I and IGFII were determined by ELISA in tumor and intact gastric tissues of 15 AC patients and 10 SRCC patients (T2-3N0-2M0, G2-3), mean age 62.8±2.38 years.

Results

Results. Levels of IGF-I, IGF-II and VEGF in intact gastric tissues were similar at AC and SRCC, but EGF and EGFR levels at AC were higher than at SRCC. Level of VEGF in AC tumor tissue, compared to intact gastric tissue, increased by 2.3 times and IGFI and IGFII decreased by 2.1 and 1.8 times, respectively. Tumor tissue of SRCC showed the increased level of EGF (by 2.9 times) and EGFR (by 1.8 times), tissue of SRCC was characterized by the activation of system of EGF and IGF, but not VEGF. Tissue of AC demonstrated the stimulation of VEGFA neoangiogenesis.

Conclusion

Conclusion. A significant difference was observed in the levels of VEGF-A, IGF-I and IGF-II and components of the EGF system in gastric tumors and visually intact tissues in G2-G3 AC and SRCC. The higher activity of the EGF and IGF systems in SRCC is probably associated with diffuse growth characteristics and the origin from neuroendocrine cells, which serves as an autocrine/paracrine regulation of invasive growth. AC with solid structure is more in need of neoangiogenesis carried out mainly by the VEGF system.

аденокарцинома желудкаперстневидноклеточный ракнеоангиогенезVEGFEGFEGFRIGFadenocarcinoma of stomachsignet-ring cell carcinoma of stomachneoangiogenesisVEGFEGFEGFRIGFReferencesTahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004; 157:327-349.Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004; 157:327-349.Gao M, Liang XJ, Zhang ZS, Ma W, Chang ZW, Zhang MZ. Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features. Asian Pac J Trop Med. 2013; 6 (4):260-264. DOI: 10.1016/S1995-7645(13)60054-1Gao M, Liang XJ, Zhang ZS, Ma W, Chang ZW, Zhang MZ. Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features. Asian Pac J Trop Med. 2013; 6 (4):260-264. DOI: 10.1016/S1995-7645(13)60054-1Yuan L-W, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: The cuffing-edge. World J Gastroenterol. 2016 Feb 14; 22 (6):2046-2059. DOI: 10.3748/wjg.v22.i6.2046Yuan L-W, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: The cuffing-edge. World J Gastroenterol. 2016 Feb 14; 22 (6):2046-2059. DOI: 10.3748/wjg.v22.i6.2046Li H, Batth IS, Qu X, Xu L, Song N, Wang R, et al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. 2017 Jan 30; 16 (1):6. DOI: 10.1186/s12943-016-0576-5Li H, Batth IS, Qu X, Xu L, Song N, Wang R, et al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. 2017 Jan 30; 16 (1):6. DOI: 10.1186/s12943-016-0576-5Lee SH, Jeong D, Han Y, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015; 89(1):1-8. DOI: 10.4174/astr.2015.89.1.1Lee SH, Jeong D, Han Y, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015; 89(1):1-8. DOI: 10.4174/astr.2015.89.1.1Isobe T, Aoyagi K, Koufuji K, Shirouzu K, Kawahara A, Taira T, et al. Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1a) expression in gastric cancer. Int J Clin Oncol. 2013; 18(2):293-304. DOI: 10.1007/s10147-012-0378-8Isobe T, Aoyagi K, Koufuji K, Shirouzu K, Kawahara A, Taira T, et al. Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1a) expression in gastric cancer. Int J Clin Oncol. 2013; 18(2):293-304. DOI: 10.1007/s10147-012-0378-8Lampri ES, Goussia AC, Agnantis NJ. Clinicopathological Study of Angiogenesis in Gastric Cancer. Int J Pathol Clin Res. 2016; 2(3). DOI: 10.23937/2469-5807/1510044Lampri ES, Goussia AC, Agnantis NJ. Clinicopathological Study of Angiogenesis in Gastric Cancer. Int J Pathol Clin Res. 2016; 2(3). DOI: 10.23937/2469-5807/1510044Kitadai Y. Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer. Cancer Microenvironment. 2010; 3 (1):109-116. DOI: 10.1007/s12307-009-0032-9Kitadai Y. Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer. Cancer Microenvironment. 2010; 3 (1):109-116. DOI: 10.1007/s12307-009-0032-9Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang M-Z, Harris RC. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev. 2016; 96(3):1025-1069. DOI: 10.1152/physrev.00030.2015Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang M-Z, Harris RC. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev. 2016; 96(3):1025-1069. DOI: 10.1152/physrev.00030.2015Zhang Z, Tang H, Lin J, Hu Y, Luo G, Luo Z, Cheng C, Wang P. Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis. Oncotarget. 2017; 8(10):17202-17215. DOI: 10.18632/oncotarget.15231Zhang Z, Tang H, Lin J, Hu Y, Luo G, Luo Z, Cheng C, Wang P. Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis. Oncotarget. 2017; 8(10):17202-17215. DOI: 10.18632/oncotarget.15231Maramoffi S, Paci M, Manzoffi G, Rapicetta C, Gugnoni M, Galeone C, et al. Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance. Int J Mol Sci. 2016; 17(4):593. DOI: 10.3390/ijms17040593Maramoffi S, Paci M, Manzoffi G, Rapicetta C, Gugnoni M, Galeone C, et al. Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance. Int J Mol Sci. 2016; 17(4):593. DOI: 10.3390/ijms17040593Maramoffi S, Paci M, Micciche F, Ciarrocchia A, Cavazzad A, De Bortolic M, et al. Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. Lung Cancer. 2012; 76(3):332—338. DOI: 10.1016/j.lungcan.2011.11.018Maramoffi S, Paci M, Micciche F, Ciarrocchia A, Cavazzad A, De Bortolic M, et al. Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. Lung Cancer. 2012; 76(3):332—338. DOI: 10.1016/j.lungcan.2011.11.018Lococo F, Paci M, Rapicetta C, Rossi T, Sancisi V, Braglia L, et al. Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer. Int. J. Mol. Sci. 2015; 16(8):19612—19630. DOI: 10.3390/ijms160819612Lococo F, Paci M, Rapicetta C, Rossi T, Sancisi V, Braglia L, et al. Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer. Int. J. Mol. Sci. 2015; 16(8):19612—19630. DOI: 10.3390/ijms160819612Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, Paez de la Cadena M. Alteration of the serum levels of the Epidermal Growth Factor Receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br. J. Cancer. 2007; 96(10):1569—1578. DOI: 10.1038/sj.bjc.6603770Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, Paez de la Cadena M. Alteration of the serum levels of the Epidermal Growth Factor Receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br. J. Cancer. 2007; 96(10):1569—1578. DOI: 10.1038/sj.bjc.6603770Jantus-Lewintre E, Sirera R, Cabrera A, Blasco A, Caballero C, Iranzo V, et al. Analysis of the prognostic value of soluble Epidermal Growth Factor Receptor plasma concentration in advanced non-small-cell lung cancer patients. Clin. Lung Cancer. 2011; 12 (5):320—327. DOI: 10.1016/j.cllc.2011.03.031Jantus-Lewintre E, Sirera R, Cabrera A, Blasco A, Caballero C, Iranzo V, et al. Analysis of the prognostic value of soluble Epidermal Growth Factor Receptor plasma concentration in advanced non-small-cell lung cancer patients. Clin. Lung Cancer. 2011; 12 (5):320—327. DOI: 10.1016/j.cllc.2011.03.031Oh MJ, Choi JH, Kim IH, Lee YH, Huh JY, Park YK, et al. Detection of Epidermal Growth Factor Receptor in the serum of patients with cervical carcinoma. Clin. Cancer Res. 2000 Dec; 6 (12):4760—4763.Oh MJ, Choi JH, Kim IH, Lee YH, Huh JY, Park YK, et al. Detection of Epidermal Growth Factor Receptor in the serum of patients with cervical carcinoma. Clin. Cancer Res. 2000 Dec; 6 (12):4760—4763.Choi JH, Oh JY, Ryu SK, Kim SJ, Lee NY, Kim YS, et al. Detection of Epidermal Growth Factor Receptor in the serum of gastric carcinoma patients. Cancer. 1997; 79 (10):1879-1883.Choi JH, Oh JY, Ryu SK, Kim SJ, Lee NY, Kim YS, et al. Detection of Epidermal Growth Factor Receptor in the serum of gastric carcinoma patients. Cancer. 1997; 79 (10):1879-1883.Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer. 2001; 37 (17):2257—2263. DOI: 10.1016/s0959-8049(01)00269-6Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer. 2001; 37 (17):2257—2263. DOI: 10.1016/s0959-8049(01)00269-6Wang H-B, Zhou C-J, Song S, Chen P, Xu W, Liu B, et al. Evaluation of Nrf2 and IGF-1 expression in benign, premalignant and malignant gastric lesions. Pathol Res Pract. 2011; 207(3):169-173. DOI: 10.1016/j.prp.2010.12.009Wang H-B, Zhou C-J, Song S, Chen P, Xu W, Liu B, et al. Evaluation of Nrf2 and IGF-1 expression in benign, premalignant and malignant gastric lesions. Pathol Res Pract. 2011; 207(3):169-173. DOI: 10.1016/j.prp.2010.12.009Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H, et al. IGF1/IGF1R/ Stat3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis. Cancer Lett. 2017; 393:76-85. DOI: 10.1016/j.canlet.2017.02.014Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H, et al. IGF1/IGF1R/ Stat3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis. Cancer Lett. 2017; 393:76-85. DOI: 10.1016/j.canlet.2017.02.014Gryko M, Kisluk J, Cepowicz D, Zinczuk J, Kamocki Z, Guzinska-Ustymowicz K, et al. Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol. 2014; 65(2):135-140. DOI: 10.5114/pjp.2014.42678Gryko M, Kisluk J, Cepowicz D, Zinczuk J, Kamocki Z, Guzinska-Ustymowicz K, et al. Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol. 2014; 65(2):135-140. DOI: 10.5114/pjp.2014.42678Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 2005 May 1; 54 (2):591-600. DOI: 10.1136/gut.2004.048926Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 2005 May 1; 54 (2):591-600. DOI: 10.1136/gut.2004.048926Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, et al. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer. 2011; 117(14):3135-3147. DOI: 10.1002/cncr.25893Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, et al. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer. 2011; 117(14):3135-3147. DOI: 10.1002/cncr.25893Pavelic K, Kolak T, Kapitanovic S, Radosevic S, Spaventi S, Kruslin B, et al. Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol. 2003; 201(3):430-438. DOI: 10.1002/path.1465Pavelic K, Kolak T, Kapitanovic S, Radosevic S, Spaventi S, Kruslin B, et al. Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol. 2003; 201(3):430-438. DOI: 10.1002/path.1465

The authors declare that there are no conflicts of interest present.